Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Tarextumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
Tarextumab: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Osanetant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
Osanetant: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Pegtarazimod Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
Pegtarazimod: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Lixosicone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
Lixosicone: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Vafidemstat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
Vafidemstat: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Pegadricase Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
Pegadricase: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Taladegib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
Taladegib: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Farletuzumab Ecteribulin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
Farletuzumab Ecteribulin: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Pesampator Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
Pesampator: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Autologus rapamycin resistant T-cell therapy (Rapa Therapeutics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
Autologus rapamycin resistant T-cell therapy (Rapa Therapeutics): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
AV-1 (AbViro) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
AV-1 (AbViro): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Nicotinamide riboside Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
Nicotinamide riboside: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.